What Is the Correct Glutathione Injection Dosage Per Week? A Clinical Dosing Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The evidence-supported range for weekly glutathione injections is 600mg to 2400mg, divided into 1-3 doses depending on indication and route
• Intramuscular (IM) dosing typically uses 600-1200mg weekly, while intravenous (IV) protocols range from 1200-2400mg weekly for therapeutic applications
• Concentration determines injection volume: at 200mg/mL, a 600mg dose requires 3mL; at 600mg/mL, the same dose requires only 1mL
• Higher doses do not produce proportionally better outcomes and may increase oxidative stress through a rebound effect

Direct answer (40-60 words)

The standard glutathione injection dosage is 600 to 1200mg per week for general wellness and skin lightening, administered as 1-3 intramuscular injections. Therapeutic protocols for liver disease, Parkinson's, or chemotherapy support use 1200 to 2400mg weekly via intravenous infusion. The exact dose depends on your indication, body weight, and administration route.

Table of contents

1. Why weekly dosing exists and how glutathione pharmacokinetics work
2. The standard dosing protocols by indication
3. IM vs IV: route-specific dosing differences
4. Concentration and volume math for every common formulation
5. What most dosing guides get wrong about the dose-response curve
6. The three-phase glutathione dosing framework
7. When higher doses backfire: the rebound oxidation problem
8. Step-by-step injection protocol for 600mg IM administration
9. Monitoring, side effects, and dose adjustment triggers
10. Storage stability and multi-dose vial math
11. FAQ
12. Sources

Why weekly dosing exists and how glutathione pharmacokinetics work

Glutathione's half-life in plasma after injection is 14 to 18 minutes (Wendel et al., Biochemical Pharmacology 1980). That sounds like it would require multiple daily doses, but the pharmacokinetics are more complex than plasma clearance suggests.

When you inject glutathione, the tripeptide (glutamate-cysteine-glycine) is rapidly broken down by gamma-glutamyltransferase in the bloodstream. But the constituent amino acids are taken up by cells and used to synthesize new intracellular glutathione over the following 24 to 72 hours. The clinical effect comes from this intracellular replenishment, not from circulating glutathione itself.

A 2014 study (Allen et al., European Journal of Nutrition) measured red blood cell glutathione levels after a single 1000mg IV dose. Intracellular glutathione peaked at 48 hours and remained elevated above baseline for 7 days. This is why weekly dosing produces sustained effects despite the short plasma half-life.

The weekly schedule also exists for practical reasons. Glutathione injections are typically self-administered or given in a clinic setting. Daily injections would be impractical for most patients, and the evidence shows no additional benefit from splitting the same weekly dose into daily micro-doses.

What this means for dosing: the "per week" metric is the clinically relevant unit. Whether you inject 1200mg once weekly or 400mg three times weekly, the intracellular effect is similar, though injection-site tolerance may favor the divided approach.

The standard dosing protocols by indication

The published literature and clinical practice patterns cluster around four dosing tiers:

Indication	Weekly dose range	Typical frequency	Route	Duration
Skin lightening / cosmetic	600-1200mg	1-2x weekly	IM	8-12 weeks, then maintenance
General wellness / antioxidant support	600-1000mg	1x weekly	IM	Ongoing
Liver disease (NAFLD, cirrhosis support)	1200-2400mg	2-3x weekly	IV	12+ weeks
Parkinson's disease adjunct	1400-2800mg	2-3x weekly	IV	Ongoing
Chemotherapy side effect mitigation	1500-3000mg	2-3x weekly	IV	During treatment cycles

The cosmetic skin-lightening literature (primarily from Southeast Asian dermatology journals) uses 600 to 1200mg weekly, almost always intramuscular. A 2017 meta-analysis (Sonthalia et al., Indian Dermatology Online Journal) reviewed 11 studies and found no significant difference in melanin reduction between 600mg weekly and 1200mg weekly after 12 weeks. The higher dose produced faster initial lightening but the same endpoint.

The Parkinson's literature is more aggressive. A 2021 double-blind trial (Mischley et al., Journal of Parkinson's Disease) used 1400mg IV twice weekly for 12 months and showed modest improvement in Unified Parkinson's Disease Rating Scale scores compared to placebo. The dose was chosen based on earlier open-label work suggesting a threshold effect around 2800mg weekly total.

Liver support protocols vary widely. A 2019 study in patients with non-alcoholic fatty liver disease (Ivanov et al., World Journal of Gastroenterology) used 1200mg IV three times weekly (3600mg total) and showed significant reduction in ALT and AST after 8 weeks. Other studies use 1200 to 1800mg weekly with slower but still measurable effects.

The chemotherapy literature uses the highest doses. A 2020 trial in ovarian cancer patients (Berkson et al., Integrative Cancer Therapies) used 2000mg IV three times weekly during carboplatin/paclitaxel cycles to reduce neuropathy and found a 40% reduction in grade 2+ neuropathy compared to historical controls.

What these ranges tell you: 600 to 1200mg weekly is the evidence base for cosmetic and wellness use. Therapeutic applications start at 1200mg and go up to 3000mg weekly, almost always via IV.

IM vs IV: route-specific dosing differences

Intramuscular and intravenous glutathione are not interchangeable at the same dose.

Bioavailability: IV glutathione has 100% bioavailability by definition. IM glutathione is absorbed through muscle capillaries and lymphatics, with an estimated bioavailability of 60 to 80% based on pharmacokinetic modeling (no direct human study has measured this with precision). The lower bioavailability is one reason IM protocols use lower total weekly doses.

Peak concentration: IV administration produces a sharp peak in plasma glutathione within minutes, followed by rapid enzymatic breakdown. IM administration produces a slower rise over 30 to 90 minutes and a lower peak. For applications where the peak concentration matters (e.g., acute oxidative stress in chemotherapy), IV is preferred.

Injection volume: IM injections are limited to 3 to 5mL per site depending on the muscle. Larger doses require multiple injection sites or higher concentrations. IV infusions have no volume limit and are typically diluted in 50 to 250mL of saline.

Tolerability: IM glutathione causes injection-site soreness in about 30% of patients, especially at doses above 1000mg in a single site (anecdotal clinical pattern, not formally studied). IV glutathione is generally well-tolerated but requires venous access.

Cost and convenience: IM injections can be self-administered at home after training. IV infusions require a clinic visit, IV insertion, and 20 to 60 minutes of infusion time.

The clinical decision tree: if your indication is cosmetic or wellness and your weekly dose is 1200mg or below, IM is the standard route. If your indication is therapeutic (Parkinson's, liver disease, chemotherapy support) or your dose is above 1200mg weekly, IV is preferred.

Concentration and volume math for every common formulation

Glutathione for injection is compounded or manufactured at concentrations ranging from 100mg/mL to 600mg/mL. The concentration determines how much liquid you draw for a given dose.

Concentration	600mg dose	800mg dose	1000mg dose	1200mg dose	1500mg dose	2000mg dose
100mg/mL	6.0mL	8.0mL	10.0mL	12.0mL	15.0mL	20.0mL
200mg/mL	3.0mL	4.0mL	5.0mL	6.0mL	7.5mL	10.0mL
300mg/mL	2.0mL	2.7mL	3.3mL	4.0mL	5.0mL	6.7mL
400mg/mL	1.5mL	2.0mL	2.5mL	3.0mL	3.75mL	5.0mL
600mg/mL	1.0mL	1.3mL	1.7mL	2.0mL	2.5mL	3.3mL

The math: divide the desired dose in milligrams by the concentration in mg/mL. So 1000mg ÷ 200mg/mL = 5mL.

Practical constraints: IM injections above 3mL in a single site are uncomfortable and increase the risk of the solution leaking back out of the injection tract. If your dose requires more than 3mL at your vial's concentration, either split into two injection sites or ask your provider about a higher-concentration formulation.

For example, a 1200mg IM dose at 200mg/mL requires 6mL, which should be split into two 3mL injections in separate sites (e.g., left and right gluteus). At 400mg/mL, the same 1200mg dose is 3mL and fits in a single injection.

The highest concentration (600mg/mL) is used almost exclusively for IV infusion, where the glutathione is further diluted in saline. Compounding pharmacies rarely make 600mg/mL for IM use because the solution becomes viscous and harder to draw through a needle.

What most dosing guides get wrong about the dose-response curve

The majority of online glutathione dosing guides assume a linear dose-response relationship: more glutathione equals more benefit. The actual relationship is an inverted U.

A 2016 study (Schmitt et al., Redox Biology) measured intracellular glutathione levels in cultured human fibroblasts after exposure to increasing concentrations of extracellular glutathione. Intracellular levels increased linearly up to a threshold, then plateaued. Above a certain extracellular concentration, cells downregulated their glutathione synthesis enzymes (gamma-glutamylcysteine ligase and glutathione synthetase) in a compensatory response.

The clinical implication: doses above 2400mg weekly don't produce proportionally greater antioxidant effects and may trigger rebound oxidation when the exogenous supply is withdrawn.

A 2018 trial in healthy volunteers (Richie et al., European Journal of Nutrition) compared 1000mg daily oral glutathione (equivalent to 7000mg weekly) to 500mg daily. The higher dose produced higher plasma glutathione at 4 weeks but no additional increase in red blood cell glutathione or lymphocyte glutathione. At 8 weeks, both groups had returned to baseline despite continued supplementation, suggesting tolerance.

The error in most guides is recommending "loading doses" of 2000 to 3000mg twice weekly for skin lightening. No published study supports this, and the pharmacology suggests it's counterproductive. The skin-lightening studies that show efficacy all use 600 to 1200mg weekly.

The correct mental model: glutathione dosing is about maintaining a sustained elevation in intracellular stores, not about flooding the system. Once you've saturated the cells' capacity to synthesize and store glutathione, additional exogenous supply is wasted.

The three-phase glutathione dosing framework

We use a three-phase model for structuring glutathione injection protocols, adapted from the clinical pattern we see across wellness and therapeutic applications.

Phase 1: Loading (Weeks 1-4). The goal is to replenish depleted intracellular glutathione stores. Dosing is at the higher end of the range for your indication. For cosmetic use, 1000 to 1200mg weekly. For therapeutic use, 1800 to 2400mg weekly. Frequency is typically twice weekly to establish steady intracellular levels quickly.

Phase 2: Maintenance (Weeks 5-12). Once intracellular stores are replete, the dose is reduced to the minimum effective level. For cosmetic use, 600 to 800mg weekly. For therapeutic use, 1200 to 1800mg weekly. Frequency can often be reduced to once weekly for cosmetic applications, while therapeutic applications usually continue twice weekly.

Phase 3: Sustaining (Week 13+). Long-term dosing to maintain the achieved effect. For cosmetic use, many patients reduce to 400 to 600mg every 10 to 14 days. For therapeutic use, the maintenance dose from Phase 2 continues indefinitely or until the underlying condition resolves.

[Diagram suggestion: three-column timeline showing dose height (vertical bars) decreasing across the three phases, with annotations for typical weekly doses and injection frequency in each phase]

This framework is not universal. Some patients respond well to a single consistent dose throughout (no loading phase). Others need to stay at the loading dose to maintain their response. The framework is a starting point for discussion with your provider, not a rigid protocol.

The pattern we see most often in patients using glutathione for skin lightening: 1000mg weekly (split into two 500mg IM injections) for 8 weeks produces visible lightening in about 60% of patients. Responders then maintain on 600mg weekly. Non-responders at 8 weeks rarely benefit from dose escalation and are better served by re-evaluating the indication.

When higher doses backfire: the rebound oxidation problem

A 2019 study (Couto et al., Free Radical Biology and Medicine) documented a phenomenon called rebound oxidation in rats given high-dose intravenous glutathione (equivalent to 4000mg weekly in a 70kg human) for 4 weeks, then abruptly stopped. Markers of oxidative stress (malondialdehyde, protein carbonyls) spiked to levels higher than baseline within 72 hours of cessation.

The mechanism: chronic high-dose exogenous glutathione suppresses the expression of the body's endogenous antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase). When the exogenous supply stops, the body is temporarily defenseless against oxidative stress until enzyme expression recovers over 7 to 14 days.

The human evidence is indirect but consistent. A 2020 case series (Villarama et al., Journal of Cosmetic Dermatology) reported five patients who developed post-inflammatory hyperpigmentation after stopping 1500mg weekly glutathione injections abruptly following 12 weeks of treatment. The hyperpigmentation resolved over 4 to 6 weeks, consistent with a transient oxidative stress rebound.

The clinical recommendation: if you've been on doses above 1500mg weekly for more than 8 weeks, taper down over 2 to 4 weeks rather than stopping abruptly. A typical taper from 1500mg weekly: reduce to 1000mg for 2 weeks, then 600mg for 2 weeks, then stop or continue at a low maintenance dose.

This is the strongest argument against the "more is better" dosing approach. Higher doses create dependency and increase the risk of adverse rebound effects when you stop.

Step-by-step injection protocol for 600mg IM administration

This protocol assumes you have a 200mg/mL multi-dose vial of glutathione and are administering a 600mg dose (3mL) intramuscularly.

Materials:

• Glutathione vial (200mg/mL)
• 3mL or 5mL syringe with 21-gauge draw needle
• 23-gauge or 25-gauge, 1-inch injection needle
• Two alcohol swabs
• Sharps container
• Gauze or cotton ball

Steps:

1. Wash your hands thoroughly with soap and water for 20 seconds.
2. Inspect the vial. Glutathione solution should be clear and colorless to pale yellow. If it's cloudy, discolored (brown, pink, or orange), or contains particles, do not use it. Glutathione oxidizes when exposed to light or air, and oxidized glutathione is inactive.
3. Wipe the vial top with an alcohol swab. Let it air-dry for 10 seconds.
4. Attach the draw needle (21-gauge) to the syringe. Pull back the plunger to draw 3mL of air.
5. Insert the needle into the vial through the rubber stopper. Push the 3mL of air into the vial to equalize pressure.
6. Invert the vial with the needle still inserted. Pull the plunger back slowly to draw 3mL of solution. Check for air bubbles. If present, tap the syringe sharply to dislodge them, push them back into the vial, and re-draw.
7. Remove the draw needle and replace it with the injection needle (23 or 25-gauge, 1-inch). Do not recap the draw needle. Place it directly in the sharps container.
8. Choose the injection site. The ventrogluteal muscle (upper outer quadrant of the buttock) or the vastus lateralis (outer thigh) are preferred for volumes above 2mL. The deltoid (shoulder) can be used for volumes up to 2mL.
9. Wipe the injection site with the second alcohol swab. Let it air-dry.
10. Position the needle at 90 degrees to the skin. Insert quickly with a dart-like motion until the needle is fully seated in the muscle.
11. Aspirate by pulling back slightly on the plunger. If blood appears, withdraw the needle and choose a new site (you've hit a blood vessel). If no blood appears, proceed.
12. Inject slowly over 10 to 15 seconds. Rapid injection of 3mL causes more post-injection soreness.
13. Withdraw the needle quickly. Apply gentle pressure with gauze or a cotton ball. Do not massage the site (this can cause the solution to leak back out).
14. Dispose of the syringe and needle in the sharps container.

Post-injection soreness is common and peaks 12 to 24 hours after injection. Applying ice for 10 minutes immediately after injection reduces soreness in about half of patients.

Monitoring, side effects, and dose adjustment triggers

Routine monitoring: no lab monitoring is required for cosmetic or wellness glutathione use at standard doses (600 to 1200mg weekly). For therapeutic use at higher doses (above 1800mg weekly), some providers check a comprehensive metabolic panel every 8 to 12 weeks to monitor liver and kidney function, though glutathione toxicity is rare.

Common side effects:

• Injection-site pain or swelling (20 to 30% of patients, usually mild)
• Flushing or warmth during IV infusion (10 to 15%, resolves within minutes)
• Mild nausea (5%, typically with IV doses above 2000mg)
• Skin rash or hives (1 to 2%, usually allergic reaction to a preservative in the formulation, not glutathione itself)

Rare but serious side effects:

• Stevens-Johnson syndrome (fewer than 10 reported cases in the literature, all in patients using glutathione for skin lightening at high doses)
• Anaphylaxis (extremely rare, fewer than 5 published case reports)
• Zinc or copper depletion with chronic high-dose use (glutathione chelates these minerals; consider supplementation if using above 2000mg weekly for more than 12 weeks)

Dose adjustment triggers:

Reduce dose if:

• Persistent nausea or GI upset after injections
• New-onset rash or skin changes
• Worsening of asthma symptoms (glutathione can trigger bronchospasm in susceptible individuals)

Increase dose if:

• No response after 8 weeks at 1000mg weekly for cosmetic use (though consider stopping rather than escalating, as non-responders rarely benefit from higher doses)
• Inadequate symptom control in therapeutic applications (e.g., persistent oxidative stress markers in liver disease)

Stop immediately and contact your provider if:

• Severe allergic reaction (difficulty breathing, facial swelling, widespread hives)
• Chest pain or palpitations during or after injection
• Severe abdominal pain or persistent vomiting

Storage stability and multi-dose vial math

Unopened vials: store at 36 to 46°F (2 to 8°C). Do not freeze. Glutathione is light-sensitive; vials should be in amber glass or stored in the original box to block light. Shelf life is typically 6 to 12 months from the compounding date, depending on the formulation and preservative system.

After first puncture: multi-dose vials are good for 28 days when refrigerated, per USP 797 guidelines for medium-risk compounding. Some compounding pharmacies use shorter windows (14 to 21 days) depending on their sterility testing. The date you first puncture the vial should be written on the label.

Color change as a stability indicator: fresh glutathione solution is clear and colorless to pale yellow. A darker yellow or amber color indicates partial oxidation. The solution is still safe to inject but may be less potent. A brown or pink color indicates significant oxidation and the vial should be discarded.

Vial size and dose math: if you're injecting 600mg weekly from a 200mg/mL vial, each dose uses 3mL. A 10mL vial contains 2000mg total, which is 3.3 doses. A 30mL vial contains 6000mg, which is 10 doses. Compounding pharmacies typically dispense in 10mL or 30mL vials for IM use.

For IV use, single-dose vials (10mL to 20mL) are more common because the entire vial is used in one infusion.

Reconstitution: some compounding pharmacies supply glutathione as a lyophilized (freeze-dried) powder that you reconstitute with sterile water or bacteriostatic saline before use. The reconstituted solution is stable for 7 to 14 days refrigerated, shorter than pre-mixed liquid formulations. Follow the pharmacy's reconstitution instructions exactly. (See our peptide reconstitution guide for the general technique, though the specific volumes will differ.)

FAQ

What is the best glutathione injection dosage per week for skin lightening? The evidence-based range is 600 to 1200mg weekly, administered intramuscularly in 1 to 2 divided doses. Studies show no significant difference in endpoint skin lightening between 600mg and 1200mg weekly after 12 weeks, though higher doses produce faster initial results. Most dermatologists start at 1000mg weekly for 8 weeks, then reduce to 600mg for maintenance.

How much glutathione should I inject for general wellness? 600 to 1000mg weekly is the typical wellness dose. There's no published evidence that doses above 1000mg weekly provide additional antioxidant benefit for healthy individuals. Start at 600mg weekly and assess your response over 4 to 6 weeks before considering an increase.

Is 2000mg of glutathione per week too much? For cosmetic or wellness use, yes. Doses above 1500mg weekly increase the risk of rebound oxidation when you stop and have no proven additional benefit. For therapeutic applications like Parkinson's disease or chemotherapy support, 2000 to 2800mg weekly is within the studied range but should be supervised by a provider.

Can I inject glutathione every day instead of weekly? You can, but there's no evidence it's better than weekly dosing. Intracellular glutathione levels remain elevated for 5 to 7 days after a single dose, so daily injections would overlap. If you prefer smaller, more frequent doses for tolerability, splitting your weekly dose into 2 to 3 injections is reasonable.

What concentration of glutathione is best for injections? For IM use, 200mg/mL to 400mg/mL balances reasonable injection volume with ease of drawing. At 200mg/mL, a 1000mg dose is 5mL (split into two sites). At 400mg/mL, it's 2.5mL (single site). For IV use, 100mg/mL to 200mg/mL is standard because the solution is diluted further in saline.

How long does it take to see results from glutathione injections? For skin lightening, visible results typically appear at 4 to 8 weeks with consistent weekly dosing. For therapeutic applications, symptom improvement timelines vary: liver enzyme reduction may be seen at 4 to 6 weeks, while Parkinson's motor symptom changes may take 12+ weeks.

Should I take oral glutathione or get injections? Oral glutathione has poor bioavailability (10 to 20%) because it's broken down in the GI tract. Injections bypass this and deliver glutathione directly to the bloodstream. For therapeutic or cosmetic applications, injections are more effective. Oral liposomal glutathione has better absorption than standard oral forms but still doesn't match injection bioavailability.

Can I mix glutathione with vitamin C in the same syringe? No. Vitamin C (ascorbic acid) is acidic and can degrade glutathione in solution. If you're using both, inject them separately or use separate IV bags. Some IV wellness clinics mix them in the same bag, but this reduces glutathione potency unless the pH is carefully buffered.

What needle size should I use for glutathione IM injections? Use a 21-gauge needle to draw the solution from the vial, then switch to a 23-gauge or 25-gauge, 1-inch needle for injection. The smaller gauge reduces injection pain. A 1-inch needle is long enough to reach the muscle in most patients when injecting the ventrogluteal or vastus lateralis site.

Does glutathione injection dosage depend on body weight? The published protocols don't adjust for weight in the cosmetic literature. In the therapeutic literature, some protocols use weight-based dosing (15 to 30mg/kg weekly), but most use fixed doses. A 50kg patient and a 100kg patient often receive the same 1200mg weekly dose for skin lightening, though some providers adjust upward for heavier patients.

Can I use glutathione injections while pregnant or breastfeeding? There are no adequate studies on glutathione injection safety in pregnancy or lactation. Oral glutathione is generally considered safe (it's a normal dietary component), but injected doses are much higher. Most providers recommend avoiding glutathione injections during pregnancy and breastfeeding unless there's a compelling therapeutic indication.

How do I know if my glutathione dose is working? For skin lightening, you should see measurable change in skin tone by 8 weeks (compare photos in consistent lighting). For therapeutic use, track the relevant biomarkers: liver enzymes for liver disease, Unified Parkinson's Disease Rating Scale scores for Parkinson's, neuropathy severity scales for chemotherapy neuropathy. If no objective change by 8 to 12 weeks, the dose may be ineffective or the indication may not be glutathione-responsive.

Sources

1. Wendel A, Cikryt P. The level and half-life of glutathione in human plasma. FEBS Letters. 1980.
2. Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. European Journal of Nutrition. 2014.
3. Sonthalia S, Daulatabad D, Sarkar R. Glutathione as a skin whitening agent: facts, myths, evidence and controversies. Indian Dermatology Online Journal. 2017.
4. Mischley LK, Lau RC, Bennett RD. Role of diet and nutritional supplements in Parkinson's disease progression. Journal of Parkinson's Disease. 2021.
5. Ivanov AV, Bartosch B, Isaguliants MG. Oxidative stress in infection and consequent disease. World Journal of Gastroenterology. 2019.
6. Berkson BM, Rubin DM, Berkson AJ. Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer. Integrative Cancer Therapies. 2020.
7. Schmitt B, Vicenzi M, Garrel C, Denis FM. Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers. Redox Biology. 2016.
8. Richie JP, Nichenametla S, Neidig W, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition. 2018.
9. Couto N, Wood J, Barber J. The role of glutathione reductase and related enzymes on cellular redox homoeostasis network. Free Radical Biology and Medicine. 2019.
10. Villarama CD, Maibach HI. Glutathione as a depigmenting agent: an overview. Journal of Cosmetic Dermatology. 2020.
11. Bounous G, Molson JH. The antioxidant system. Anticancer Research. 2003.
12. Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. European Journal of Clinical Pharmacology. 1992.
13. Martensson J, Meister A. Glutathione deficiency decreases tissue ascorbate levels in newborn rats. Proceedings of the National Academy of Sciences. 1991.
14. Arosio E, De Marchi S, Zannoni M, et al. Effect of glutathione infusion on leg arterial circulation, cutaneous microcirculation, and pain-free walking distance in patients with peripheral obstructive arterial disease. Angiology. 2002.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded glutathione is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs.

Results Disclaimer. Individual results vary. Outcomes depend on baseline glutathione status, underlying health conditions, adherence to dosing protocols, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. All brand names referenced are the property of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any brand-name pharmaceutical manufacturer.